Drug Trial Radar · NCT07951086
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Jan 26, 2027
Primary completion
May 18, 2028
Study completion Jun 15, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2 study is: 1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with moderate to severe active rheumatoid arthritis (RA). 2. to provide information about dose selection and study design for subsequent clinical development.
Conditions
- Rheumatoid Arthritis
Interventions
DDY391Drug
DDY391
PlaceboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants achieving American College of Rheumatology 50 (ACR50) responseTime frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.